CN Patent

CN112566902A — 作为核转运调节剂的化合物及其用途

Assigned to XWPharma Ltd · Expires 2021-03-26 · 5y expired

What this patent protects

提供了式I’‑III’的化合物及其制备和用途，和包含这些化合物的药物组合物及其作为核转运调节剂的用途。还提供了这些化合物或药物组合物治疗或预防人中某些神经障碍和疾病以及某些类型的癌症中的用途。

USPTO Abstract

提供了式I’‑III’的化合物及其制备和用途，和包含这些化合物的药物组合物及其作为核转运调节剂的用途。还提供了这些化合物或药物组合物治疗或预防人中某些神经障碍和疾病以及某些类型的癌症中的用途。

Drugs covered by this patent

Patent Metadata

Patent number
CN112566902A
Jurisdiction
CN
Classification
—
Expires
2021-03-26
Drug substance claim
No
Drug product claim
No
Assignee
XWPharma Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.